Mounjaro®
Starting from £179.99/mo
Start journey Learn moreYes, you can stop Wegovy after losing weight, but the clinical evidence is clear: most people regain a significant portion of the weight they lost once the medicine is discontinued. Trials published in the New England Journal of Medicine show that semaglutide's appetite-suppressing effect reverses when treatment ends, because the underlying biology doesn't change. These are prescription-only medicines, so decisions about stopping, pausing or continuing Wegovy are made with a prescriber, not unilaterally.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
A 2022 withdrawal study — the STEP 4 trial extension — followed adults who had lost weight on semaglutide 2.4mg and then stopped the medicine. Within 48 weeks of discontinuation, participants regained on average two-thirds of their lost weight, and many of the improvements in blood pressure, blood sugar and waist circumference reversed in parallel. The researchers described this as a predictable consequence of stopping a medicine that works by modulating a chronic biological system, not by permanently retraining it.
The practical implication is straightforward: Wegovy controls appetite and slows gastric emptying while you're taking it. Once the medicine is gone from your system, those signals return to their pre-treatment state. Hunger comes back. Fullness arrives later. Calorie intake tends to creep up, often without the person noticing a dramatic change in how they're eating. This isn't a failure of willpower; it reflects how the biology of weight regulation actually works.
You can read how the medicine behaves during active treatment on our page about losing weight on Wegovy, which covers what to expect week by week.
Not to the same degree. A minority of people do maintain most of their loss after stopping, particularly those who have made substantial and sustainable changes to their eating patterns, activity levels, and relationship with food during treatment. The medicine creates a window; what you build inside that window matters.
Clinical guidance from the NHS medicines page for semaglutide notes that Wegovy is intended to be used alongside a reduced-calorie diet and increased physical activity. Treatment works best when those habits are genuinely embedded rather than paused for the duration. People who use the lower-hunger period to establish new routines (regular meals, adequate protein, consistent movement) tend to fare better after stopping than those who relied mainly on the medicine's appetite suppression.
That said, the data are honest: sustained weight maintenance after stopping is the exception rather than the rule for most people. If you're wondering what happens when your weight loss slows or plateaus during treatment, that's a separate but related question worth exploring.
NICE's guidance on semaglutide (Wegovy), published as technology appraisal TA875, recommends it for a maximum of two years within NHS specialist weight management services. Private use doesn't carry that hard cut-off, but it does require ongoing prescriber oversight. At each review, a clinician should be asking: is the person continuing to benefit, are they tolerating it well, and does continuing make clinical sense?
Some people do use Wegovy for longer periods under private clinical supervision. Others reach a stable weight, feel confident in their habits, and choose to stop with a plan in place. A small number are advised to stop because the medicine no longer suits them clinically. All three paths are legitimate. None should be decided in isolation from a prescriber, which is why the specific question of stopping after reaching your goal deserves a proper clinical conversation rather than a self-directed change.
One thing our prescribers hear regularly: people who stop Wegovy abruptly, without a structured plan, tend to struggle more than those who taper thoughtfully or at least have a strategy for the weeks that follow. If you're spending more time outdoors as your activity levels increase, it's also worth reading our guidance on Wegovy and sun exposure, as there are a few practical considerations worth knowing about. The medicine lives in the fridge door next to everyday things; when it's gone, the habits it supported need to stand on their own.
For context on what maintenance typically looks like once you've reached your target, our page on what weight loss after Wegovy tends to look like in practice covers the longer-term picture in detail, and if you want practical guidance on losing weight after Wegovy, including how to approach the period once treatment ends, that's worth reading alongside it. If you're weighing up Wegovy against other licensed options, our treatment overview sets out the choices clearly.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.